We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » DDMAC: FERTILITY DRUG RISKS MINIMIZED IN PROMOTIONS
DDMAC: FERTILITY DRUG RISKS MINIMIZED IN PROMOTIONS
January 2, 2004
Promotional materials for Organon's Follistim fertility drug minimized the drug's risks and made unsubstantiated superiority claims, according to an untitled letter released by the FDA late December.